ACCEPTED MANUSCRIPT
[26] X.P. Han, J. Sun, Y.J. Wang, Z.G. He, Med. Res. Rev. 35 (2015) 1268-
O-(benzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium tetrafluoroborate
TBTU
1299.
[27] L.L. Ma, R. Ma, Y.P. Wang, X.Y. Zhu, J.L. Zhang, H.C. Chan, X.F.
Chen, W.J. Zhang, S.K. Chiu, G.Y. Zhu, Chem. Commun. 51 (2015)
6301-6304.
AA
DMF
ascorbic acid
N,N-dimethylformamide
[28] R.K. Pathak, S. Marrache, J.H. Choi, T.B. Berding, S. Dhar, Angew.
Chem. Int. Ed. 53 (2014) 1963-1967.
[29] R. Raveendran, J.P. Braude, E. Wexselblatt, V. Novohradsky, O.
Stuchlikova, V. Brabec, V. Gandin, D. Gibson, Chem. Sci. 7 (2016)
2381-2391.
[30] S.G. Awuah, Y.R. Zheng, P.M. Bruno, M.T. Hemann, S.J. Lippard, J.
Am. Chem. Soc. 137 (2015) 14854-14857.
[31] G. Frumento, R. Rotondo, M. Tonetti, G. Damonte, U. Benatt, G.B.
Ferrara, J. Exp. Med. 196 (2002) 459-468.
[32] M. Ravera, E. Gabano, G. Pelosi, F. Fregonese, S. Tinello, D. Sella,
Inorg. Chem. 53 (2014) 9326-9335.
[33] A. Lopez-Flores, R. Jurado, P. Garcia-Lopez, J. Pharmacol. Toxicol. 52
(2005) 366-372.
Acknowledgments
We are grateful to the National Natural Science Foundation of
China (Grant Nos. 21571033 and 81503099) for financial aids to
this work. The research was also supported by Jiangsu Province
Natural Science Foundation (Grant no. BK20150643). The
authors would also like to thank the Fundamental Research
Funds for the Central Universities (Project 2242017K41024) for
supplying basic facilities to our key laboratory.
[34] X.C. Huang, R.Z. Huang, S.H. Gou, Z.M. Wang, Z.X. Liao, H.S. Wang,
Bioconjugate. Chem. 28 (2017) 1305-1323.
[35] J.S. Li, Q. Han, J.M. Fang, M. Rizzi, A.A. James, J.Y. Li, Arch. Insect.
Biochem. 64 (2006) 74-87.
[36] H. Lee, H.Lee, Y. Kwon, J.H. Lee, J.J. Kim, M.K. Shin, S.H. Kim, H.
Bae, J. Immunol. 185 (2010) 6698-6705.
[37] X.D. Liu, N. Shin, H.K. Koblish, G.J. Yang, Q. Wang, K. Wang, L.
Leffet, M.J. Hansbury, B. Thomas, M. Rupar, P. Waeltz, K.J. Bowman,
P. Polam, R.B. Sparks, E.W. Yue, Y.L. Li, R.Wynn, J.S. Fridman, T.C.
Burn, A.P. Combs, R.C. Newton, P.A. Scherle, Blood. 115 (2010) 3520-
3530.
Supplementary information
1
Diagrams of ESI-MS, H, and 13C spectra. HPLC analyses on
the stability of Pt(IV) complexes under reduction with ascorbic
acid. Western blot expression of TDO, kynurenine inhibition,
mixed leukocyte reaction to estimate T-cell proliferation and
platinum contents data. This material is available free of charge
via the Internet.
References
[1] J.C. Frankel, Science. 342 (2013) 1432-1433.
[2] M.S. Kim, J.S. Ma, H. Yun, Y. Cao, J.Y. Kim, V. Chi, D. Wang, A.
Woods, L. Sherwood, D. Caballero, J. Gonzalez, P.G. Schultz, T.S.
Young, C.H. Kim, J. Am. Chem. Soc. 137 (2015) 2832-2835.
[3] B.S.L. Topalian, J.M. Taube, R.A. Anders, D.M. Pardoll, Nat. Rev.
Cancer. 16 (2016) 275-287.
Tables:
Table 1. In vitro cytotoxicity of Pt(IV) complexes against human cancer cell
lines.
[4] L.P. Kane, J. Immunol. 184 (2010) 2743-2749.
[5] J.S. Wu, S.Y. Lin, F.Y. Liao, W.C. Hsiao, L.C. Lee, Y.H. Peng, C.L.
Hsieh, M.H. Wu, J.S. Song, A. Yueh, C.H. Chen, S.H. Yeh, C.Y. Liu,
S.Y. Lin, T.K. Yeh, J.T. Hsu, C. Shih, S.H. Ueng, M.S. Hung, S.Y. Wu,
J. Med. Chem. 58 (2015) 7807-7819.
Figure and Scheme captions:
Fig. 1. The releasing ability of 2-3 under reduction with ascorbic acid (AA).
[6] P. Sharma, J.P. Allison, Science. 348 (2015) 56-61.
[7] S.J. Thackray, C.G. Mowat, S.K. Chapman, Biochem. Soc. Trans. 36
(2008) 1120-1123.
Fig. 2. Cell uptake of cisplatin, 2 and 3 in HepG-2 cells for 12 h. Results are
expressed as the mean ± SD for three independent experiments.
[8] R. Schwarcz, J.P. Bruno, P.J. Muchowski, H.Q. Wu, Nat. Rev. Neurosci.
139 (2012) 465-477.
[9] A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, R.M. Lemoli,
Blood 113 (2009) 2394-2401.
[10] W.E. Knox, A.H. Mehler, J. Biol. Chem. 187 (1950) 419-430.
[11] M. Kanai, H. Funakoshi, H. Takahashi, T. Hayakawa, S. Mizuno, K.
Matsumoto, T. Nakamura, Mol. Brain. 2 (2009) 1-16.
[12] A. Maeta, T. Fukuwatari, H. Funakoshi, T. Nakamura, K. Shibata, Int. J.
Tryptophan Res. 6 (2013) 55-65.
[13] C.A. Opitz, U.M. Litzenburger, F. Sahm, M. Ott, I. Tritschler, S. Trump,
T. Schumacher, L. Jestaedt, D. Schrenk, M. Weller, M. Jugold, G.J.
Guillemin, C.L. Miller, C. Lutz, B. Radlwimmer, I. Lehmann, A.
Deimling, W. Wick, M. Platten, Nature 478 (2011) 197-203.
[14] L. Pilotte, P. Larrieu, V. Stroobant, D. Colau, E. Dolusic, R. Frederick,
E.D. Plaen, C. Uyttenhove, J. Wouters, B. Masereel, B.J. VandenEynde,
Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 2497-2502.
[15] S.K. Schmidt, A. Müller, K. Heseler, C. Woite, K. Spekker, C.R.
MacKenzie, W. Däubener, Eur. J. Immunol. 39 (2009) 2755-2764.
[16] X.Y. Wang, X.H. Wang, Z.J. Guo, Acc. Chem. Res. 48 (2015) 2622-
2631.
Fig. 3. Cell cycle distribution of HepG-2 cells after treated with cisplatin or 3
at 10 μM for 24 h.
Fig. 4. Flow cytometric histograms of apoptotic HepG-2 cells after treated
with cispatin (5 μM) and 3 (5 μM) for 24 h. Lower left (Q4), living cells;
lower right (Q3), early apoptotic cells; upper right (Q2), late apoptotic cells;
upper left (Q1), necrotic cells. Inserted numbers in the profiles indicate the
percentage of the cells present in this area. Data are expressed as the mean ±
SEM for five independent experiments.
Fig. 5. Western blot analysis of the expression of related proteins with
complex 3 at 10 μM for 24 h.
Fig. 6. (A) TDO inhibitory potency (IC50 data) of compounds 1, 2 and 3. (B)
Western blot analysis of TDO expression in HepG-2 cancer cells after treated
with measured compounds at 10 μM for 24 h. (C) Kynurenine inhibition of 1
and 3 (10 μM) assessed by HPLC. Results are expressed as the mean ± SD
for three independent experiments. P<0.05.
Fig. 7. qRT-PCR of mRNA expression level of TDO after exposure to 3 (10
μM) in HepG-2 cells for 24 h. P<0.05.
[17] M. Galanski, M.A. Jakupec, B.K. Keppler, Curr. Med. Chem. 12 (2005)
2075-2094.
[18] L. Kelland, Nat. Rev. Cancer. 7 (2007) 573-584.
Fig. 8. qRT-PCR of mRNA expression level of AHR after exposure to 3 (10
μM) in HepG-2 cells for 24 h. P<0.05.
[19] M.A. Fuertes, C. Alonso, J.M. Perez, Chem. Rev. 103 (2003) 645-662.
[20] D. Shen, I. Pastan, M.M. Gottesman, Cancer. Res. 58 (1998) 268-275.
[21] F.F. Liu, S.H. Gou, F.H. Chen, L. Fang, J. Zhao, J. Med. Chem. 58
(2015) 6368-6377..
[22] D. Wang, S.J. Lippard, Nat. Rev. Drug. Discov. 4 (2005) 307-320.
[23] E.R. Jamieson, S.J. Lippard, Chem. Rev. 99 (1999) 2467-2498.
[24] Z.H. Siddik, Oncogene 22 (2003) 7265-7279.
Fig. 9. Mixed leukocyte reactions to estimate T-cell proliferation after
measured compounds (10 μM) incubated with PBMCs and HepG-2 cells by
measuring cell marker CD4/8+ (A) and CFSE-labeled CD3+ T (B) cells using
flow cytometry
[25] Y. Yuan, R.T.K. Kwok, B.Z. Tang, B. Liu, J. Am. Chem. Soc. 136 (2014)
2546-2554.
Scheme 1. Synthesis of TDO-targeted Pt(IV) complexes 2 - 4.
8 / 10